DEXTROSE- dextrose monohydrate injection, solution
Baxter Healthcare Corporation

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use DEXTROSE INJECTION 70% safely and effectively. See full prescribing information for DEXTROSE INJECTION 70%.

DEXTROSE injection, for intravenous use
Initial U.S. Approval: 1940

INDICATIONS AND USAGE
Dextrose Injection is indicated as a source of calories when mixed with amino acids or other compatible intravenous fluids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated. (1)

DOSAGE AND ADMINISTRATION

• Pharmacy Bulk Package. Not for direct intravenous infusion. (2.1)
• For slow intravenous infusion only into a: (2.2)
  o Central vein, if final dextrose concentration is greater than 5% or osmolality is greater than 900 mOsm/L approximately.
  o Peripheral vein, if final dextrose concentration 5% or less and osmolality is less than 900 mOsm/L approximately.
• Individualize dosage based on the patient’s clinical condition, body weight, nutritional/fluid requirements, as well as additional energy given orally/enterally. (2.3)
• Discontinue infusion of concentrated dextrose solutions slowly. (2.4)

DOSAGE FORMS AND STRENGTHS

• Injection: 70% (0.7 grams/mL), 70 grams of dextrose hydrous per 100 mL in a 2000 mL Pharmacy Bulk Package flexible container. (3)

CONTRAINDICATIONS

Severe dehydration. (4)

WARNINGS AND PRECAUTIONS

• Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. (5.1)
• Hypoglycemia or Hyperosmolar Hyperglycemic State: Monitor blood glucose and administer insulin as needed. (5.2)
• Hypersensitivity Reactions: Monitor for signs and symptoms and discontinue infusion if reactions occur. (5.3)
• Vein Damage and Thrombosis: Administer solutions containing more than 5% dextrose as the final concentration or solutions with an osmolity of approximately 900 mOsm/L or greater through a central vein. (2.2, 5.4)
• Hyponatremia: Monitor serum sodium to minimize the risk of hypo- or hyperosmotic hyponatremia. (5.5)
• Risk of Infection: Monitor for signs and symptoms and laboratory parameters. (5.6)
• Refeeding Syndrome: Monitor laboratory parameters. (5.7)
• Hepatobiliary Disorders: Monitor liver function parameters and ammonia levels. (5.8)
• Aluminum Toxicity: Dextrose Injection contains aluminum that may be toxic. Adult patients with impaired renal function and preterm infants are at higher risk. Limit aluminum to less than 4 mcg/kg/day (5.9, 8.4)
• Parenteral Nutrition Associated Liver Disease: Increased risk in patients who receive parenteral nutrition for extended periods of time, especially preterm infants; monitor liver function tests, if abnormalities occur consider discontinuation or dosage reduction. (5.10, 8.4)
• Electrolyte Imbalance and Fluid Overload: Monitor daily fluid balance, blood electrolyte levels, correct as needed. (5.11, 8.4)

ADVERSE REACTIONS
The most common adverse reactions are, hyperglycemia, hypersensitivity reactions, infection both systemic and at the injection site, and vein thrombosis or phlebitis. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance: Monitor blood glucose
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
   2.1 Preparation Instructions Prior to Administration
   2.2 Important Administration Instructions
   2.3 Dosing Instructions
   2.4 Discontinuation of Dextrose Injection
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
   5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates
   5.2 Hyperglycemia and Hyperosmolar Hyperglycemic State
   5.3 Hypersensitivity Reactions
   5.4 Vein Damage and Thrombosis
   5.5 Hyponatremia
   5.6 Risk of Infections
   5.7 Refeeding Syndrome
   5.8 Hepatobiliary Disorders
   5.9 Aluminum Toxicity
   5.10 Risk of Parenteral Nutrition Associated Liver Disease
   5.11 Electrolyte Imbalance and Fluid Overload
6 ADVERSE REACTIONS
7 DRUG INTERACTIONS
   7.1 Other Products that Affect Glycemic Control or Fluid and/or Electrolyte Balance
8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
   8.4 Pediatric Use
   8.5 Geriatric Use
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
Dextrose Injection is indicated as source of calories and fluid replenishment when mixed with amino acids or other compatible intravenous fluids for patients requiring parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated.

2 DOSAGE AND ADMINISTRATION

2.1 Preparation Instructions Prior to Administration

Dextrose Injection is supplied as a pharmacy bulk package for admixing only and is not for direct intravenous infusion. Dextrose Injection is intended for use in the preparation of sterile, intravenous admixtures. Prior to administration, Dextrose Injection must be transferred to a separate PN container, diluted with other compatible intravenous fluids and used as an admixture in PN solutions.

- Do not remove from overpouch until ready to use.
- Tear protective overwrap at slit and remove solution container. Small amounts of moisture may be found on the solution container from water permeating from inside the container. The amount of permeated water is insufficient to affect the solution significantly. If larger amounts of water are found, the container should be checked for tears or leaks.
- Inspect Dextrose Injection prior to use. Opacity of the container may be observed due to moisture absorption during the sterilization process. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Evaluate the following:
  - If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired.
  - Check for minute leaks by squeezing the inner container firmly. If leaks are found, discard solution as sterility may be impaired.
  - Do not use unless solution is clear and container is intact.
- Because additives may be incompatible, evaluate all additions for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. If it is deemed advisable to introduce additives, use aseptic technique and mix thoroughly.
- Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates [see Warnings and Precautions (5.1)].

Preparation for Admixing

1. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area).
2. Suspend container from eyelet support.
3. Remove plastic protector from outlet port at bottom of container.
4. Attach solution transfer set. Refer to complete directions accompanying set. Note: The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.
5. The VIAFLEX plastic container should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry notation.
6. Once container closure has been penetrated, withdrawal of contents should be completed without delay. After initial entry, maintain contents at room temperature (25°C/77°F) and dispense within 4 hours.

2.2 Important Administration Instructions
2.3 Dosing Instructions

Caution: Dextrose Injection is not for direct intravenous infusion. Prior to administration, Dextrose Injection must be diluted with other compatible intravenous fluids and used as an admixture in PN solutions.

Dextrose Injection is a part of the parenteral nutrition (PN) regimen which also includes amino acids, electrolytes, and possibly lipid emulsion. Protein, caloric, fluid and electrolyte requirements all need to be taken into consideration when determining individual patient dosage needs.

Individualize the dosage of Dextrose Injection based on the patient’s clinical condition (ability to adequately metabolize dextrose), body weight, nutritional and fluid requirements, as well as additional energy given orally or enterally to the patient. Vitamins and trace elements and other components (including amino acids, electrolytes, and lipid emulsion) can be added to the PN solution to meet nutrient needs and prevent deficiencies and complications from developing.

The administration rate should be governed, especially during the first few days of therapy, based on the patient’s tolerance to dextrose. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of blood glucose levels.

In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria.

2.4 Discontinuation of Dextrose Injection

To reduce the risk of hypoglycemia, a gradual decrease in flow rate in the last hour of infusion should be considered [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

3 DOSAGE FORMS AND STRENGTHS

Dextrose Injection 70%, USP is a sterile, non-pyrogenic, hypertonic solution of 70 grams of dextrose hydrous per 100 mL (0.7 grams/mL) in a 2000 mL Pharmacy Bulk Package flexible container.

4 CONTRAINDICATIONS

The use of Dextrose Injection is contraindicated in patients:
5 WARNINGS AND PRECAUTIONS

5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates
Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes due to pulmonary embolism have occurred. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.1, 2.2)], the infusion set and catheter should also periodically be checked for precipitates.

5.2 Hyperglycemia and Hyperosmolar Hyperglycemic State
The use of dextrose infusions in patients with impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death.

Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration and electrolyte losses [see Warnings and Precautions (5.11)]. Patients with underlying CNS disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state.

Monitor blood glucose levels and treat hyperglycemia to maintain levels within normal limits while administering Dextrose Injection. Insulin may be administered or adjusted to maintain optimal blood glucose levels during Dextrose Injection administration.

5.3 Hypersensitivity Reactions
Hypersensitivity and infusion reactions including anaphylaxis have been reported with dextrose injection [see Adverse Reactions (6)]. Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop. Signs or symptoms may include: pruritis, bronchospasm, cyanosis, angioedema, hypotension, pyrexia, chills, and rash.

5.4 Vein Damage and Thrombosis
Dextrose Injection is for admixture with amino acids or dilution with other compatible intravenous fluids. It is not for direct intravenous infusion. Administer solutions with an osmolarity of ≥ 900 mOsm/L through a central vein [see Dosage and Administration (2.2)]. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

5.5 Hyponatremia
Dextrose Injection is a hypertonic solution [see Description, Table 1 (11)]. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolism. Monitoring of serum sodium is particularly important for hypotonic fluids.
Depending on the tonicity of the solution, the volume and rate of infusion, and depending on a patient’s underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances, most importantly hypo- or hyperosmotic hyponatremia.

The risk for hyponatremia is increased, in pediatric patients, elderly patients, postoperative patients, those with psychogenic polydipsia and in patients treated with medications that increase the risk of hyponatremia (such as certain diuretic, antiepileptic and psychotropic medications). Close clinical monitoring may be warranted.

Acute hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury. Patients at increased risk for developing complications of hyponatremia, such as hyponatremic encephalopathy include pediatric patients; women, in particular, premenopausal women; patients with hypoxemia; and in patients with underlying central nervous system disease [see Use in Specific Populations (8.4)].

Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications such as osmotic demyelination syndrome with risk of seizures and cerebral edema. To avoid complications, monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.

High volume infusion must be used with close monitoring in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatremia.

5.6 Risk of Infections

Patients who require parenteral nutrition are at high risk of infections because the nutritional components of these solutions can support microbial growth. Infection and sepsis may also occur as a result of the use of intravenous catheters to administer parenteral nutrition.

The risk of infection is increased in patients with malnutrition-associated immunosuppression, hyperglycemia exacerbated by dextrose infusion, long-term use and poor maintenance of intravenous catheters, or immunosuppressive effects of other concomitant conditions, drugs, or other components of the parenteral formulation (e.g., lipid emulsion).

To decrease the risk of infectious complications, ensure aseptic technique in catheter placement and maintenance, as well as aseptic technique in the preparation and administration of the nutritional formula.

Monitor for signs and symptoms (including fever and chills) of early infections, including laboratory test results (including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device and insertion site for edema, redness and discharge.

5.7 Refeeding Syndrome

Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intakes including Dextrose Injection.

5.8 Hepatobiliary Disorders

Hepatobiliary disorders are known to develop in some patients without preexisting liver disease who receive parenteral nutrition, including cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure. The etiology of these disorders is thought to be multifactorial and may differ between patients.

Monitor liver function parameters and ammonia levels. Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify
possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

5.9 Aluminum Toxicity

Dextrose Injection contains no more than 25 mcg/L of aluminum. However, with prolonged parenteral administration in patients with renal impairment, the aluminum contained in Dextrose Injection may reach toxic levels. Preterm infants are at greater risk because their kidneys are immature, and they require large amounts of concomitant calcium and phosphate solutions that contain aluminum. Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system (CNS) and bone toxicity. Tissue loading may occur at even lower rates of administration of total parenteral nutrition products [see Use in Specific Populations (8.4)].

5.10 Risk of Parenteral Nutrition Associated Liver Disease

Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis. The exact etiology is not entirely clear and is likely multifactorial. If Dextrose Injection-treated patients develop abnormal liver function tests, consider discontinuation or dosage reduction.

5.11 Electrolyte Imbalance and Fluid Overload

Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.

Depending on the volume and rate of infusion, the intravenous administration of concentrated dextrose solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations (including hypoosmotic hyponatremia), overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations in the administered solution. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations in the solution.

Monitor blood electrolyte levels, glucose, acid-base balance, correct fluid and electrolyte imbalances, and administer essential vitamins and minerals as needed. Monitor daily fluid balance. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose and/or free water load. Patients at increased risk for developing hyponatremic encephalopathy include pediatric patients; elderly patients, women, in particular premenopausal women; patients with hypoxemia; and patients with underlying CNS disease [see Use in Specific Populations (8.4, 8.5)].

6 ADVERSE REACTIONS

The following adverse reactions associated with the use of Dextrose Injection were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.1)]
- Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.2)]
- Hypersensitivity reactions [see Warnings and Precautions (5.3)]
- Vein damage and thrombosis [see Warnings and Precautions (5.4)]
- Hyponatremia and hyponatremic encephalopathy [see Warnings and Precautions (5.5)]
- Risk of infections [see Warnings and Precautions (5.6)]
7 DRUG INTERACTIONS

7.1 Other Products that Affect Glycemic Control or Fluid and/or Electrolyte Balance

Dextrose Injection can affect glycemic control and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.5, 5.11)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose Injection in patients treated with other substances that affect glycemic control, or fluid and/or electrolyte balance (such as diuretics and anti-epileptics).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Appropriate administration of Dextrose Injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. However, maternal hyperglycemia secondary to infusion of glucose-containing products at the time of delivery has been associated with adverse neonatal outcomes such as neonatal hypoglycemia. Malnutrition in pregnant women is associated with adverse maternal and fetal outcomes (see Clinical Considerations). Animal reproduction studies have not been conducted with injectable dextrose solutions.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo/Fetal Risk

Severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. Parenteral nutrition should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake.

8.2 Lactation

Risk Summary

There are no data on the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of Dextrose Injection to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Dextrose Injection and any potential adverse effects on the breastfed infant from Dextrose Injection or from the underlying maternal condition.

8.4 Pediatric Use

The safety profile of Dextrose Injection in pediatric patients is similar to adults.
Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to avoid potential long-term adverse effects.

Plasma electrolyte concentrations should be closely monitored in pediatric patients who may have impaired ability to regulate fluids and electrolytes. In very low birth weight infants, excessive or rapid administration of Dextrose Injection may result in increased serum osmolality and risk of intracerebral hemorrhage.

Because of immature renal function, preterm infants receiving prolonged treatment with dextrose injection, may be at risk of aluminum toxicity [see Warnings and Precautions (5.9)]. Patients, including pediatric patients, may be at risk for Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.10)].

Children (including neonates and older children) are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy.

8.5 Geriatric Use

Clinical studies of Dextrose Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly patients are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy [see Warnings and Precautions (5.5)]. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

10 OVERDOSAGE

An increased infusion rate of Dextrose Injection or administration of a concentrated dextrose solution can cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance [see Warnings and Precautions (5.2, 5.11)].

Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal. Discontinue infusion and institute appropriate corrective measures such as administration of exogenous insulin.

Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to CNS, respiratory and cardiovascular systems.

If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.

11 DESCRIPTION

Dextrose Injection 70%, USP is a clear, sterile, nonpyrogenic, hypertonic solution of Dextrose, USP in Water for Injection in a flexible plastic container as a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program. Dextrose Injection is not for direct intravenous infusion [see Dosage and Administration (2.1)].

The Pharmacy Bulk Package is designed to facilitate admixture or dilution to provide dextrose in
various concentrations and is available in a 2000 mL size. See Table 1 for the content and characteristics of this solution.

The solution contains no bacteriostatic, antimicrobial agent or added buffer and is intended only for use following admixture or dilution. The pH range is 4.0 (3.2 to 6.5).

Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly.

Table 1. Contents and Characteristics of Dextrose Injection 70%, USP

<table>
<thead>
<tr>
<th>Strength</th>
<th>Fill Volume</th>
<th>Amount of Dextrose Hydrous, USP per container</th>
<th>kcal* per Container</th>
<th>Osmolarity (mOsmol per liter) (calc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose Injection 70%, USP (0.7 grams/mL)</td>
<td>2000 mL</td>
<td>1400 grams</td>
<td>4760</td>
<td>3530</td>
</tr>
</tbody>
</table>

* Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous

Dextrose, USP is chemically designated D-glucose, monohydrate (C₆H₁₂O₆ • H₂O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. It has the following structural formula:

![Dextrose Structural Formula](image)

Water for Injection, USP is chemically designated H₂O.
Dextrose Injection 70%, USP contains no more than 25 mcg/L of aluminum.
Dextrose is derived from corn.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Dextrose Injection is used to supplement nutrition by providing glucose parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.
16 HOW SUPPLIED/STORAGE AND HANDLING

Dextrose Injection 70%, USP (0.7 grams/mL) is available in a Pharmacy Bulk Package flexible plastic container for intravenous administration after appropriate dilution [see Dosage and Administration (2.1)] and is available in the following size in Table 2 below.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Code</th>
<th>Volume</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose Injection 70%, USP (0.7 grams/mL)</td>
<td>2B0296</td>
<td>2000 mL</td>
<td>0338-0719-06</td>
</tr>
</tbody>
</table>

Do not remove container from the overwrap until ready to use.

Store at room temperature (25°C /77°F).

Do not freeze.

Avoid excessive heat.

For storage of admixed solution, see Dosage and Administration (2.1).

17 PATIENT COUNSELING INFORMATION

Inform patients, caregivers, or home healthcare providers of the following risks of Dextrose Injection:

- Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.1)]
- Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.2)]
- Hypersensitivity reactions [see Warnings and Precautions (5.3)]
- Vein damage and thrombosis [see Warnings and Precautions (5.4)]
- Hyponatremia [see Warnings and Precautions (5.5)]
- Risk of infections [see Warnings and Precautions (5.6)]
- Refeeding syndrome [see Warnings and Precautions (5.7)]
- Hepatobiliary disorders [see Warnings and Precautions (5.8)]
- Aluminum toxicity [see Warnings and Precautions (5.9)]
- Risk of parenteral nutrition associated liver disease [see Warnings and Precautions (5.10)]
- Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.11)]

Manufactured by, Packed by, Distributed by:

Baxter Healthcare Corporation
Deerfield, IL 60015 USA
07-19-73-116

Baxter and Viaflex are trademarks of Baxter International Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
Container Label

LOT
EXP

2B0296
NDC 0338-0719-06

2000 mL
DIN 02014874

DEXTROSE
Injection USP
70%

Pharmacy Bulk Package
Not For Direct Infusion
Must Be Diluted

Rx Only

Each 100 mL contains 70 g DEXTROSE HYDROUS USP
In water for injection USP
pH 4.0 (3.2 to 5.0) SPECIFIC GRAVITY 1.24 (CALC)
HYPERTONIC OSMOLARITY 3500 mOsmol/L (CALC)
STERILE NONPYROGENIC
CONTAINS NO MORE THAN 25 µg/L OF ALUMINUM
COLOR VARIATION FROM LIGHT YELLOW TO AMBER IS NORMAL
AND DOES NOT ALTER EFFICACY
DOSENG AND ADMINISTRATION SEE PACKAGE INSERT
CAUTION DO NOT USE UNLESS SOLUTION IS CLEAR CLOSURE
IS INTACT AND CONTAINER IS UNDAMAGED
CHECK FOR MINUTE LEAKS BY SQUEEZING FIRMLY
IF LEAKS ARE FOUND DISCARD AS STERILITY MAY BE IMPAIRED
AFFIX ACCOMPANYING LABEL FOR DATE AND TIME OF ENTRY
WITHIN 4 HOURS AFTER INITIAL ENTRY DISCARD CONTAINER
AND UNUSED CONTENTS
STORE UNIT IN MOISTURE BARRIER OVERWRAP AT
ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE
AVOID EXCESSIVE HEAT PROTECT FROM FREEZING

VIAFLEX CONTAINER PL 146 PLASTIC

Baxter
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
BAXTER PL 146
AND VIAFLEX ARE TRADEMARKS OF BAXTER
INTERNATIONAL INC

DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
MISSISSAUGA ON L5G 0C2

Container Label
Not For Direct Infusion
Must Be Diluted

Rx Only

Each 100 mL contains 70 g dextrose hydrous USP in water for injection USP

pH 4.0 (3.2 to 6.5) specific gravity 1.24 (calc)

Hypertonic osmolarity 3530 mOsmol/L (calc)

Sterile nonpyrogenic

Contains no more than 25 µg/L of aluminum

Color variation from light yellow to amber is normal and does not alter efficacy

Dosage and Administration see package insert

Caution do not use unless solution is clear closure is intact and container is undamaged

Check for minute leaks by squeezing firmly
If leaks are found discard as sterility may be impaired

Affix accompanying label for date and time of entry

Within 4 hours after initial entry discard container and unused contents

Store unit in moisture barrier overwrap at room temperature (25°C/77°F) until ready to use
Avoid excessive heat protect from freezing

Viaflex container

PL 146 plastic

Baxter logo

Baxter Healthcare Corporation
Deerfield IL 60015 USA

Distributed in Canada by Baxter Corporation
Mississauga, ON L5N 0C2

Made in USA

Baxter PL 146
And Viaflex are trademarks of Baxter International Inc

70%
**2B0296H**

6 – 2000 ML
VIAFLEX CONTAINER

70% DEXTROSE INJECTION, USP
(70% DEXTROSE IN WATER)

PROTECT FROM FREEZING

EXP
XXXXXX

SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX

LOT
XXXXXX

PRIMARY BAR CODE
(01) 50303380719063

Carton Label

**2B0296H**

6 - 2000ML
VIAFLEX CONTAINER

70% DEXTROSE INJECTION, USP
(70% DEXTROSE IN WATER)

PROTECT FROM FREEZING

EXP
XXXXXX

SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX

LOT
XXXXXX

PRIMARY BAR CODE
(01) 50303380719063

**DEXTROSE**
dextrose monohydrate injection, solution

<table>
<thead>
<tr>
<th><strong>Product Information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
<td>HUMAN PRESCRIPTION DRUG</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>INTRAVENOUS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Active Ingredient/Active Moiety</strong></th>
<th></th>
</tr>
</thead>
</table>
### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)</td>
<td>DEXTROSE MONOHYDRATE</td>
<td>70 g in 100 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water (UNII: 059QF0KO00)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0338-0719-06</td>
<td>2000 mL in 1 BAG; Type 0: Not a Combination Product</td>
<td>07/02/1991</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA020047</td>
<td>07/02/1991</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler

Baxter Healthcare Corporation (005083209)

### Establishment

#### Name: Baxter Healthcare Corporation

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxter Healthcare Corporation</td>
<td></td>
<td>059140764</td>
<td>ANALYSIS(0338-0719), LABEL(0338-0719), MANUFACTURE(0338-0719), PACK(0338-0719), STERILIZE(0338-0719)</td>
</tr>
</tbody>
</table>

#### Name: Baxter Healthcare Corporation

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxter Healthcare Corporation</td>
<td></td>
<td>194684502</td>
<td>ANALYSIS(0338-0719)</td>
</tr>
</tbody>
</table>

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxter Healthcare Corporation</td>
<td></td>
<td>189326168</td>
<td>ANALYSIS(0338-0719), MANUFACTURE(0338-0719), LABEL(0338-0719), PACK(0338-0719), STERILIZE(0338-0719)</td>
</tr>
</tbody>
</table>

Revised: 8/2019

Baxter Healthcare Corporation